Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias

MS-275 is a benzamide derivative with potent histone deacetylase (HDAC) inhibitory and antitumor activity in preclinical models. We conducted a phase 1 trial of orally administered MS-275 in 38 adults with advanced acute leukemias. Cohorts of patients were treated with MS-275 initially once weekly ×...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Gojo, Ivana, Jiemjit, Anchalee, Trepel, Jane B., Sparreboom, Alex, Figg, William D., Rollins, Sandra, Tidwell, Michael L., Greer, Jacqueline, Chung, Eun Joo, Lee, Min-Jung, Gore, Steven D., Sausville, Edward A., Zwiebel, James, Karp, Judith E.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2007
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1852211/
https://ncbi.nlm.nih.gov/pubmed/17179232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-05-021873
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы